Core Viewpoint - Beihai Kangcheng (01228) has seen its stock price increase by over 19%, with a year-to-date gain exceeding 2000% as of the latest report [1] Group 1: Stock Performance - As of the latest update, Beihai Kangcheng's stock is up 15.51%, trading at 2.83 HKD, with a transaction volume of 66.91 million HKD [1] Group 2: Regulatory Developments - The National Healthcare Security Administration has established a new directory for innovative commercial insurance drugs, officially starting the application process on July 11 [1] - Three of Beihai Kangcheng's products, namely Gerening (injectable Vilarozime β), Mairibei (oral Chloramphenicol solution), and Hairuisi (injectable Idursulfase β), passed the initial review on August 12, which could expedite their market access [1] Group 3: Strategic Partnerships - On August 13, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million HKD to acquire shares in Beihai Kangcheng [1] - The agreement includes an exclusive commercialization service contract, allowing a subsidiary of Baiyang Pharmaceutical to promote specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1]
港股异动 | 北海康成(01228)再涨超19% 年内累涨逾20倍 三款产品通过商保创新药目录初审